Navigation

Published technology appraisals

This table lists published NICE technology appraisals. The list can be sorted by title (alphabetically), issue date and review date. You can also:

  • click the appraisal title for full details
  • click a column heading to sort the list by that column

Please note that the 'review date' is not the date when a review of it the appraisal starts, but the date NICE consults on a proposal for reviewing it. There is no guarantee that at the review date, a review will be undertaken. Appraisals which have been considered for review and where the decision has been not to carry out a review at this time are listed in static technology appraisals.

More information on the published appraisals list.

For technology appraisal guidance organised by category, use Find guidance in the main header area above.

Searching for specific technology appraisal guidance?

Published appraisals

Results 161-180 of 311

Ref Title Date Issued Review
TA161 Osteoporosis - secondary prevention including strontium ranelate (TA161) Jan 2011 TBC
TA162 Lung cancer (non-small-cell) - erlotinib (TA162) Nov 2008 Jun 2010
TA163 Ulcerative colitis (acute exacerbations) - infliximab (TA163) Dec 2008 TBC
TA164 Hyperuricaemia - febuxostat (TA164) Dec 2008 TBC
TA165 Organ preservation (renal) - machine perfusion and static storage (TA165) Nov 2008 TBC
TA166 Hearing impairment - cochlear implants (TA166) Jan 2009 TBC
TA167 Abdominal aortic aneurysm - endovascular stent-grafts (TA167) Feb 2009 Jan 2012
TA168 Influenza - zanamivir, amantadine and oseltamivir (review) (TA168) Feb 2009 Nov 2013
TA169 Renal cell carcinoma - sunitinib (TA169) Mar 2009 Feb 2011
TA170 Venous thromboembolism - rivaroxaban (TA170) Apr 2009 Feb 2012
TA171 Multiple myeloma - lenalidomide (TA171) Jun 2009 Feb 2012
TA172 Head and neck cancer (squamous cell carcinoma) - cetuximab (TA172) Jun 2009 Jun 2012
TA173 Hepatitis B - tenofovir disoproxil fumarate (TA173) Jul 2009 Mar 2012
TA174 Leukaemia (chronic lymphocytic, first line) - rituximab (TA174) Jul 2009 TBC
TA175 Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) (TA175) Jul 2009 TBC
TA176 Colorectal cancer (first line) - cetuximab (TA176) Aug 2009 Aug 2012
TA177 Eczema (chronic) - alitretinoin (TA177) Aug 2009 Aug 2012
TA178 Renal cell carcinoma (TA178) Aug 2009 Jun 2011
TA179 Gastrointestinal stromal tumours - sunitinib (TA179) Sep 2009 Aug 2011
TA180 Psoriasis - ustekinumab (TA180) Sep 2009 Jan 2010

This page was last updated: 23 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.